L-arginine therapy in acute myocardial infarction: The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial

Steven P Schulman, Lewis Becker, David A Kass, Hunter C. Champion, Michael L. Terrin, Sandra Forman, Kavita V. Ernst, Mark D. Kelemen, Susan N. Townsend, Anne Capriotti, Joshua M. Hare, Gary Gerstenblith

Research output: Contribution to journalArticle

Abstract

Context: The amino acid L-arginine is a substrate for nitric oxide synthase and is increasingly used as a health supplement. Prior studies suggest that L-arginine has the potential to reduce vascular stiffness. Objective: To determine whether the addition of L-arginine to standard postinfarction therapy reduces vascular stiffness and improves ejection fraction over 6-month follow-up in patients following acute ST-segment elevation myocardial infarction. Design and Setting: Single-center, randomized, double-blind, placebo-controlled trial with enrollment from February 2002 to June 2004. Patients: A total of 153 patients following a first ST-segment elevation myocardial infarction were enrolled; 77 patients were 60 years or older. Intervention: Patients were randomly assigned to receive L-arginine (goal dose of 3 g 3 times a day) or matching placebo for 6 months. Main Outcome Measures: Change in gated blood pool-derived ejection fraction over 6 months in patients 60 years or older randomized to receive L-arginine compared with those assigned to receive placebo. Secondary outcomes included change in ejection fraction in all patients enrolled, change in noninvasive measures of vascular stiffness, and clinical events. Results: Baseline characteristics, vascular stiffness measurements, and left ventricular function were similar between participants randomized to receive placebo or L-arginine. The mean (SD) age was 60 (13.6) years; of the participants, 104 (68%) were men. There was no significant change from baseline to 6 months in the vascular stiffness measurements or left ventricular ejection fraction in either of the 2 groups, including those 60 years or older and the entire study group. However, 6 participants (8.6%) in the L-arginine group died during the 6-month study period vs none in the placebo group (P=.01). Because of the safety concerns, the data and safety monitoring committee closed enrollment. Conclusions: L-Arginine, when added to standard postinfarction therapies, does not improve vascular stiffness measurements or ejection fraction and may be associated with higher postinfarction mortality. L-Arginine should not be recommended following acute myocardial infarction.

Original languageEnglish (US)
Pages (from-to)58-64
Number of pages7
JournalJournal of the American Medical Association
Volume295
Issue number1
DOIs
StatePublished - Apr 1 2006

Fingerprint

Blood Vessels
Arginine
Vascular Stiffness
Randomized Controlled Trials
Myocardial Infarction
Placebos
Therapeutics
Clinical Trials Data Monitoring Committees
Safety
Left Ventricular Function
Nitric Oxide Synthase
Stroke Volume
Outcome Assessment (Health Care)
Amino Acids
Mortality
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

L-arginine therapy in acute myocardial infarction : The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial. / Schulman, Steven P; Becker, Lewis; Kass, David A; Champion, Hunter C.; Terrin, Michael L.; Forman, Sandra; Ernst, Kavita V.; Kelemen, Mark D.; Townsend, Susan N.; Capriotti, Anne; Hare, Joshua M.; Gerstenblith, Gary.

In: Journal of the American Medical Association, Vol. 295, No. 1, 01.04.2006, p. 58-64.

Research output: Contribution to journalArticle

Schulman, Steven P ; Becker, Lewis ; Kass, David A ; Champion, Hunter C. ; Terrin, Michael L. ; Forman, Sandra ; Ernst, Kavita V. ; Kelemen, Mark D. ; Townsend, Susan N. ; Capriotti, Anne ; Hare, Joshua M. ; Gerstenblith, Gary. / L-arginine therapy in acute myocardial infarction : The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial. In: Journal of the American Medical Association. 2006 ; Vol. 295, No. 1. pp. 58-64.
@article{30f3dae5307e461081d7413453c4fab0,
title = "L-arginine therapy in acute myocardial infarction: The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial",
abstract = "Context: The amino acid L-arginine is a substrate for nitric oxide synthase and is increasingly used as a health supplement. Prior studies suggest that L-arginine has the potential to reduce vascular stiffness. Objective: To determine whether the addition of L-arginine to standard postinfarction therapy reduces vascular stiffness and improves ejection fraction over 6-month follow-up in patients following acute ST-segment elevation myocardial infarction. Design and Setting: Single-center, randomized, double-blind, placebo-controlled trial with enrollment from February 2002 to June 2004. Patients: A total of 153 patients following a first ST-segment elevation myocardial infarction were enrolled; 77 patients were 60 years or older. Intervention: Patients were randomly assigned to receive L-arginine (goal dose of 3 g 3 times a day) or matching placebo for 6 months. Main Outcome Measures: Change in gated blood pool-derived ejection fraction over 6 months in patients 60 years or older randomized to receive L-arginine compared with those assigned to receive placebo. Secondary outcomes included change in ejection fraction in all patients enrolled, change in noninvasive measures of vascular stiffness, and clinical events. Results: Baseline characteristics, vascular stiffness measurements, and left ventricular function were similar between participants randomized to receive placebo or L-arginine. The mean (SD) age was 60 (13.6) years; of the participants, 104 (68{\%}) were men. There was no significant change from baseline to 6 months in the vascular stiffness measurements or left ventricular ejection fraction in either of the 2 groups, including those 60 years or older and the entire study group. However, 6 participants (8.6{\%}) in the L-arginine group died during the 6-month study period vs none in the placebo group (P=.01). Because of the safety concerns, the data and safety monitoring committee closed enrollment. Conclusions: L-Arginine, when added to standard postinfarction therapies, does not improve vascular stiffness measurements or ejection fraction and may be associated with higher postinfarction mortality. L-Arginine should not be recommended following acute myocardial infarction.",
author = "Schulman, {Steven P} and Lewis Becker and Kass, {David A} and Champion, {Hunter C.} and Terrin, {Michael L.} and Sandra Forman and Ernst, {Kavita V.} and Kelemen, {Mark D.} and Townsend, {Susan N.} and Anne Capriotti and Hare, {Joshua M.} and Gary Gerstenblith",
year = "2006",
month = "4",
day = "1",
doi = "10.1001/jama.295.1.58",
language = "English (US)",
volume = "295",
pages = "58--64",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - L-arginine therapy in acute myocardial infarction

T2 - The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial

AU - Schulman, Steven P

AU - Becker, Lewis

AU - Kass, David A

AU - Champion, Hunter C.

AU - Terrin, Michael L.

AU - Forman, Sandra

AU - Ernst, Kavita V.

AU - Kelemen, Mark D.

AU - Townsend, Susan N.

AU - Capriotti, Anne

AU - Hare, Joshua M.

AU - Gerstenblith, Gary

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Context: The amino acid L-arginine is a substrate for nitric oxide synthase and is increasingly used as a health supplement. Prior studies suggest that L-arginine has the potential to reduce vascular stiffness. Objective: To determine whether the addition of L-arginine to standard postinfarction therapy reduces vascular stiffness and improves ejection fraction over 6-month follow-up in patients following acute ST-segment elevation myocardial infarction. Design and Setting: Single-center, randomized, double-blind, placebo-controlled trial with enrollment from February 2002 to June 2004. Patients: A total of 153 patients following a first ST-segment elevation myocardial infarction were enrolled; 77 patients were 60 years or older. Intervention: Patients were randomly assigned to receive L-arginine (goal dose of 3 g 3 times a day) or matching placebo for 6 months. Main Outcome Measures: Change in gated blood pool-derived ejection fraction over 6 months in patients 60 years or older randomized to receive L-arginine compared with those assigned to receive placebo. Secondary outcomes included change in ejection fraction in all patients enrolled, change in noninvasive measures of vascular stiffness, and clinical events. Results: Baseline characteristics, vascular stiffness measurements, and left ventricular function were similar between participants randomized to receive placebo or L-arginine. The mean (SD) age was 60 (13.6) years; of the participants, 104 (68%) were men. There was no significant change from baseline to 6 months in the vascular stiffness measurements or left ventricular ejection fraction in either of the 2 groups, including those 60 years or older and the entire study group. However, 6 participants (8.6%) in the L-arginine group died during the 6-month study period vs none in the placebo group (P=.01). Because of the safety concerns, the data and safety monitoring committee closed enrollment. Conclusions: L-Arginine, when added to standard postinfarction therapies, does not improve vascular stiffness measurements or ejection fraction and may be associated with higher postinfarction mortality. L-Arginine should not be recommended following acute myocardial infarction.

AB - Context: The amino acid L-arginine is a substrate for nitric oxide synthase and is increasingly used as a health supplement. Prior studies suggest that L-arginine has the potential to reduce vascular stiffness. Objective: To determine whether the addition of L-arginine to standard postinfarction therapy reduces vascular stiffness and improves ejection fraction over 6-month follow-up in patients following acute ST-segment elevation myocardial infarction. Design and Setting: Single-center, randomized, double-blind, placebo-controlled trial with enrollment from February 2002 to June 2004. Patients: A total of 153 patients following a first ST-segment elevation myocardial infarction were enrolled; 77 patients were 60 years or older. Intervention: Patients were randomly assigned to receive L-arginine (goal dose of 3 g 3 times a day) or matching placebo for 6 months. Main Outcome Measures: Change in gated blood pool-derived ejection fraction over 6 months in patients 60 years or older randomized to receive L-arginine compared with those assigned to receive placebo. Secondary outcomes included change in ejection fraction in all patients enrolled, change in noninvasive measures of vascular stiffness, and clinical events. Results: Baseline characteristics, vascular stiffness measurements, and left ventricular function were similar between participants randomized to receive placebo or L-arginine. The mean (SD) age was 60 (13.6) years; of the participants, 104 (68%) were men. There was no significant change from baseline to 6 months in the vascular stiffness measurements or left ventricular ejection fraction in either of the 2 groups, including those 60 years or older and the entire study group. However, 6 participants (8.6%) in the L-arginine group died during the 6-month study period vs none in the placebo group (P=.01). Because of the safety concerns, the data and safety monitoring committee closed enrollment. Conclusions: L-Arginine, when added to standard postinfarction therapies, does not improve vascular stiffness measurements or ejection fraction and may be associated with higher postinfarction mortality. L-Arginine should not be recommended following acute myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=29944434110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29944434110&partnerID=8YFLogxK

U2 - 10.1001/jama.295.1.58

DO - 10.1001/jama.295.1.58

M3 - Article

C2 - 16391217

AN - SCOPUS:29944434110

VL - 295

SP - 58

EP - 64

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 1

ER -